ArticleBMC women's health2026
Improvement in health‑related quality of life in patients with heavy menstrual bleeding after treatment and its association with hereditary bleeding disorders.
Article in BMC women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
backgroundThe prevalence of hereditary bleeding disorders (HBDs) in heavy menstrual bleeding (HMB) and their impact on health-related quality of life (HRQoL) remain underexplored. We investigated the HRQoL of women with non-structural HMB and its association with HBDs.
methodA prospective longitudinal study of 100 women with HMB without structural gynecological pathology. HMB was defined as ≥ 8 days of bleeding or a PBAC score > 100 points. Four HRQoL questionnaires —SF-12®v2, EQ-5D-3 L, MBQ, and SAMANTA— were administered at baseline and 6 months. HBD diagnosis included hypermobility spectrum disorders, von Willebrand disease, platelet disorders, congenital coagulation factor deficiencies, and hyperfibrinolysis.
result88 women required treatment for HMB, anemia, or iron deficiency. Combined hormonal therapy (43%) and levonorgestrel intrauterine devices (14%) were the most frequently used treatments. Thirty-one women (31%) were diagnosed with HBD. After 6 months of treatment, SF-12®v2 results showed significant improvements in the mental and physical health components, particularly with respect to mobility, moderate activities, and pain perception. EQ-5D-3 L evaluations revealed significant improvements in anxiety and depression. MBQ and SAMANTA scores indicated significant reductions in menstrual bleeding and enhanced quality of life. However, at T6, HBD patients showed significantly lower improvements compared with non-HBD patients in physical health (SF-12 PCS, p = 0.035), EQ-5D index scores (p = 0.024), PBAC (p = 0.049), and MBQ (p = 0.028).
conclusionHBD is an important cause of HMB. Medical treatment improves mobility, moderate activities, pain perception, and anxiety/depression after 6 months, although HRQoL improvements are less pronounced in HBD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.